Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I LOVE THIS: The principals, directors and advisors of Lexington
BioSciences have been individually and collectively
involved in raising extensive capital funding for their
private and public companies. Team members have held
numerous executive leadership positions encompassing
biotechnology, and medical device companies, as well as
multi-national corporations. The team includes inventors,
scientists, and business people who have successfully
started, built and grown multiple life science companies.
Lexington's President Eric Willis comments, "The rapid approval of our clinical study submission speaks volumes to our team's diligent attention to the design of the product and required documentation, as well as the format of the proposed study itself. We are planning to immediately move ahead into the investigative phase of our studies aimed at achieving eventual FDA clearance for our HeartSentry device. This means we are proceeding rapidly toward our strategic goals. Our thorough planning means we are also in great shape to act on the approval right away. We are very happy to begin this most critical phase of our development to-date and look forward to the work ahead."
As previously noted, approval by an IRB, or ethics board, is necessary before human research can begin. The IRB has reviewed Lexington's submission for both medical safety and protection of the patients involved in the study and has subsequently advised of its approval as submitted. With approval in-hand, the Company has engaged a clinical investigative team and research site in preparation for the process of volunteer enrollment.
Good morning Italian!
Good morning LXGTF!!!
To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead. Please also follow us on Facebook, Twitter and LinkedIn.
website: https://lexingtonbiosciences.com/
LXGTF Article by Jonathan Maltz, "What is Endothelial Function..." : https://lexingtonbiosciences.com/news/endothelial-function-important-health/
CHECK THIS OUT: LXGTF Executive Summary: https://lexingtonbiosciences.com/wp-content/uploads/2017/10/Lexington-BioSciences-Overview-v6.pdf
I LOVE THE LXGTF video: https://vimeo.com/183611304
still in same mode lol
ADAC looks to be unstoppable, green again over +4%
Green opening, breaking the .42 resistance
As previously noted, approval by an IRB, or ethics board, is necessary before human research can begin. The IRB has reviewed Lexington's submission for both medical safety and protection of the patients involved in the study and has subsequently advised of its approval as submitted. With approval in-hand, the Company has engaged a clinical investigative team and research site in preparation for the process of volunteer enrollment.
Lexington's President Eric Willis comments, "The rapid approval of our clinical study submission speaks volumes to our team's diligent attention to the design of the product and required documentation, as well as the format of the proposed study itself. We are planning to immediately move ahead into the investigative phase of our studies aimed at achieving eventual FDA clearance for our HeartSentry device. This means we are proceeding rapidly toward our strategic goals. Our thorough planning means we are also in great shape to act on the approval right away. We are very happy to begin this most critical phase of our development to-date and look forward to the work ahead."
To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead. Please also follow us on Facebook, Twitter and LinkedIn.
Morning Blockchain lol
this will be amazing
This guy is awesome
Good morning Italian!
Lexington Biosciences, Inc. (CNSX:LNB.CN) (OTCQB:LXGTF) (the "Company" or "Lexington"), a development-stage medical device company, is pleased to announce entry into a strategic business relationship with a San Francisco arm of Navigant Consulting Inc., formerly Quorum Consulting. The intent of the relationship is to work with the relevant authorities towards developing a coverage policy in support of the planned commercial rollout of Lexington's HeartSentry endothelial function measurement product. Read this and more news for Lexington Biosciences at: http://www.marketnewsupdates.com/news/lxgtf.html
Multi-Billion Dollar Global Medical Device Industry Led By Cardiovascular Monitoring Devices
PR Newswire - Thu Dec 7, 8:20AM CST
Global revenues for the medical device market are already a multi-billion dollar industry and the sector aims to continue its growth through leverage created through mergers and acquisitions, as well as the development of new products with improved efficiency. Increase in geriatric population and rise in number of patients suffering from chronic disorders, such as spine disorders, diabetes, and cardiovascular diseases, are expected to drive the market growth. In terms of application, the cardiovascular segment is expected to register the highest CAGR. The medical device sector as a whole has long been one of the more lucrative markets in the overall healthcare industry, as technology and research have propelled the market to new heights. With the rising influence of technology, the players in the medical device market are constantly diversifying and include some big tech names as of late. Active healthcare companies today with current developments include: Lexington Biosciences, Inc. (CNSX:LNB.CN) (OTC:LXGTF), Immunomedics Inc. (NASDAQ:IMMU), Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), BioTelemetry Inc. (NASDAQ:BEAT), VistaGen Therapeutics Inc. (NASDAQ:VTGN).
THIS IS TRUST WORTHY! The principals, directors and advisors of Lexington
BioSciences have been individually and collectively
involved in raising extensive capital funding for their
private and public companies. Team members have held
numerous executive leadership positions encompassing
biotechnology, and medical device companies, as well as
multi-national corporations. The team includes inventors,
scientists, and business people who have successfully
started, built and grown multiple life science companies.
Good morning LXGTF!
simple truth
Amazing potential
big volume, little down
Thundercleese I agree with you completely
this guy is awesome, super smart...
still green but churning here, what I understood is that this is going on for some time already here?
Volume: 1,179,288, UP 11.11%
That's my favorite stock, +7,78%
That's my favorite stock, +7,78%
WOW, LOVE IT! The principals, directors and advisors of Lexington
BioSciences have been individually and collectively
involved in raising extensive capital funding for their
private and public companies. Team members have held
numerous executive leadership positions encompassing
biotechnology, and medical device companies, as well as
multi-national corporations. The team includes inventors,
scientists, and business people who have successfully
started, built and grown multiple life science companies.
With the news of additional product offerings, Adama plans for the CryX marketplace to focus on mid to high end consumer products that can all be bought and sold utilizing the CryX token. Mr. Sills continued, “We are envisioning a customer experience where anyone, anywhere, and at any time, can log into their app, trade and exchange tokens, shop for their favorite products, move tokens or cash between wallets and transfer money to their connected card, bank, and utilize other online wallet accounts. We want to allow crypto transactions to be easy, accessible and secure to all of our users and customers. Our vision is to bring this great technology, flexibility and freedom into a mainstream experience that is just one click or one download away.”
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium - the vital innermost lining of a person's cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.
this is a crucial point for huge jump
I think this stock have a great potential, my attention is on it, we can see more in this days
Good morning Italian, yes ...this is what we see us in